BEVACIZUMAB, PARACETAMOL , MK-2870, DEXAMETHASONE, BEVACIZUMAB , -, -, MK-2870, -
MK-2870-022
Phase 3 small_molecule active
Quick answer
BEVACIZUMAB, PARACETAMOL , MK-2870, DEXAMETHASONE, BEVACIZUMAB , -, -, MK-2870, - for Ovarian cancer recurrent is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Ovarian cancer recurrent
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active